Serlopitant

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

neurokinin-1 receptor antagonist; NK1 receptor antagonist:

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Neurokinin-1 receptor antagonist that may be used in patients with severe chronic itching that does not respond to antihistamines or topical glucocorticoids.

Serlopitant is a "small molecule" that is highly potent and selectively antagonizes the NK1 receptor. The substance can easily pass the blood-brain barrier and binds > 90% of the NK1 receptors. This signalling pathway is an essential component in the development of itching.

Field of application/useThis section has been translated automatically.

In a larger multicenter study, patients were treated with either serlopitant (0.25, 1 or 5 mg) or placebo. The drug was administered once daily for six weeks as monotherapy or with steroids and emollients of medium potency. This showed a dose-dependent decrease in itching (Yosipovitch G et al. 2018).

Dosage and method of useThis section has been translated automatically.

Dosage: 1.0 mg - 5.0 mg/day.

LiteratureThis section has been translated automatically.

  1. Frenkl TL et al (2010) A Multicenter, Double-Blind, Randomized, Placebo Controlled Trial of a Neurokinin-1 Receptor Antagonist for Overactive Bladder. The Journal of Urology 184: 616-622.
  2. Payton S et al (2010) Urinary Incontinence: Neurokinin Receptor Antagonist Inferior to Tolterodine for OAB. Nature Reviews Urology 7: 418.
  3. Yosipovitch G et al (2018) Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial. J Am Acad Dermatol 78:882-891.

Authors

Last updated on: 29.10.2020